



## HIV Vaccine

Guest Editor:

### Dr. Chitra Upadhyay

Department of Medicine, Division  
of Infectious Diseases, Icahn  
School of Medicine at Mount  
Sinai, One Gustave L Levy Place,  
Box 1090, New York, NY 10029E,  
USA

Deadline for manuscript  
submissions:

**closed (28 February 2021)**

### Message from the Guest Editor

This Special Issue of Vaccines on the “HIV vaccine” aims to highlight the unprecedented challenges and the advances that have been made in HIV-1 vaccine field since the RV144 trial. The issue will include research articles, reviews, and short communications on topics including, but not limited to, novel approaches to elicit protective innate, humoral, and cellular responses; the induction of neutralizing and non-neutralizing antibodies and their roles in protection; epitope-based and antibody lineage-based HIV-1 vaccine approaches; and advances in vaccine vectors and adjuvants. The issue will also highlight the unique challenges associated with HIV-1 vaccine development including the high mutability, extreme glycosylation, and poor immunogenicity of HIV-1, the lack of a validated animal model that can fully recapitulate the infection and pathogenesis of HIV in humans, and the lack of definitive correlates of vaccine protection. Thus, this issue will showcase the incredible achievements made in the HIV-1 vaccine field in the last decade.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)